484 related articles for article (PubMed ID: 15301592)
1. Epidemiological characteristics of leprosy reactions: 15 years experience from north India.
Kumar B; Dogra S; Kaur I
Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):125-33. PubMed ID: 15301592
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M; Berhe D
Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
[TBL] [Abstract][Full Text] [Related]
3. Histoid leprosy: a retrospective study of 40 cases from India.
Kaur I; Dogra S; De D; Saikia UN
Br J Dermatol; 2009 Feb; 160(2):305-10. PubMed ID: 19016704
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for erythema nodosum leprosum.
Manandhar R; LeMaster JW; Roche PW
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
[TBL] [Abstract][Full Text] [Related]
5. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.
Pocaterra L; Jain S; Reddy R; Muzaffarullah S; Torres O; Suneetha S; Lockwood DN
Am J Trop Med Hyg; 2006 May; 74(5):868-79. PubMed ID: 16687695
[TBL] [Abstract][Full Text] [Related]
6. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
7. Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT.
Balagon M; Saunderson PR; Gelber RH
Lepr Rev; 2011 Sep; 82(3):213-21. PubMed ID: 22125929
[TBL] [Abstract][Full Text] [Related]
8. Reaction cases treated at the Regional Leprosy Training and Research Institute, Aska, Orissa: a retrospective analysis.
Santaram V; Porichha D
Indian J Lepr; 2004; 76(4):310-20. PubMed ID: 16119141
[TBL] [Abstract][Full Text] [Related]
9. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
Vijayakumaran P; Manimozhi N; Jesudasan K
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
[TBL] [Abstract][Full Text] [Related]
10. Some unusual type 2 reactions in leprosy.
Ramesh V; Pahwa M
Int J Dermatol; 2010 Feb; 49(2):172-5. PubMed ID: 20465641
[TBL] [Abstract][Full Text] [Related]
11. Epidemiologic characteristics of leprosy reactions.
Scollard DM; Smith T; Bhoopat L; Theetranont C; Rangdaeng S; Morens DM
Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):559-67. PubMed ID: 7868954
[TBL] [Abstract][Full Text] [Related]
12. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
[TBL] [Abstract][Full Text] [Related]
13. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
de Carsalade GY; Achirafi A; Flageul B
Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
[TBL] [Abstract][Full Text] [Related]
14. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Sampaio EP; Malta AM; Sarno EN; Kaplan G
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
[TBL] [Abstract][Full Text] [Related]
15. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
Kaur I; Dogra S; Kumar B; Radotra BD
Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
[TBL] [Abstract][Full Text] [Related]
16. Occurrence and management of leprosy reaction in China in 2005.
Shen J; Liu M; Zhou M; Wengzhong L
Lepr Rev; 2009 Jun; 80(2):164-9. PubMed ID: 19743620
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
[TBL] [Abstract][Full Text] [Related]
18. Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month Minocycline and Ofloxacin.
Katoch K; Katoch VM; Natarajan M; Gupta UD; Sharma VD; Singh HB
Indian J Lepr; 2008; 80(4):331-44. PubMed ID: 20329382
[TBL] [Abstract][Full Text] [Related]
19. Unexplained delayed nerve impairment in leprosy after treatment.
Rosenberg NR; Faber WR; Vermeulen M
Lepr Rev; 2003 Dec; 74(4):357-65. PubMed ID: 14750581
[TBL] [Abstract][Full Text] [Related]
20. Relapse of lepromatous leprosy after WHO/MDT with rapid bacterial growth.
Oliveira ML; Pierro AP; Silveira PA; Campos MM; Vilela MF
Lepr Rev; 2002 Dec; 73(4):386-8. PubMed ID: 12549846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
